NEW YORK, NY / ACCESSWIRE / August 8, 2019 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. To determine your eligibility and get free access to our shareholder support tools that provide you with case updates, automated loss calculations and claims recovery assistance, please contact the firm via the links below. There will be no cost or obligation to you.
Realogy Holdings Corp. (RLGY)
Lawsuit on behalf of: investors who purchased February 24, 2017 - May 22, 2019
Lead Plaintiff Deadline : September 9, 2019
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/realogy-holdings-corp-loss-form?prid=2847&wire=1
According to the filed complaint, during the class period, Realogy Holdings Corp. made materially false and/or misleading statements and/or failed to disclose that: (1) Realogy was engaged in anticompetitive behavior by requiring property sellers to pay the commissions of a buyer’s broker at an inflated rate; (2) Realogy’s anticompetitive actions would prompt the U.S. Department of Justice (“DOJ”) to open an antitrust investigation into the real estate industry’s practices regarding brokers’ commissions; and (3) as a result, Defendants’ statements about the Realogy’s business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
Mallinckrodt Public Limited Company (MNK)
Lawsuit on behalf of: investors who purchased February 28, 2018 - July 16, 2019
Lead Plaintiff Deadline : September 24, 2019
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/mallinckrodt-public-limited-company-loss-form?prid=2847&wire=1
According to the filed complaint, during the class period, Mallinckrodt Public Limited Company made materially false and/or misleading statements and/or failed to disclose that: (i) Acthar posed significant safety concerns that rendered it a non-viable treatment for ALS; (ii) accordingly, Mallinckrodt overstated the viability of Acthar as an ALS treatment; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times.
Cardinal Health, Inc. (CAH)
Lawsuit on behalf of: investors who purchased March 2, 2015 - May 2, 2018
Lead Plaintiff Deadline : September 30, 2019
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/cardinal-health-inc-loss-form?prid=2847&wire=1
According to the filed complaint, during the class period, Cardinal Health, Inc. made materially false and/or misleading statements and/or failed to disclose that: 1) following Cardinal's acquisition of Cordis, the RFID [radio-frequency identification] inventory tracking technology and advanced supply chain solutions that Defendants told investors the Company would to use to improve Cordis’s performance were never implemented across Cordis; 2) Cordis’s antiquated and ineffective global supply chain was causing operational and inventory problems at Cordis; 3) as a result, Cordis manufactured and accumulated excessive amounts of cardiovascular product inventories, which sat on the shelf and became unsellable and/or expired; 4) the Company materially overstated Cordis’s inventory balances; 5) Cordis was not “performing well” and its integration was not “on track,” “going incredibly well” or “largely on plan"; and 6) to correct Cordis’s deficiencies, the Company would have to make substantial investments in Cordis’s IT and supporting infrastructure, thereby incurring significant Selling, General and Administrative Expenses charges beyond the levels internally budgeted or projected by Cardinal and diminishing operating earnings.
You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
SOURCE: Levi & Korsinsky, LLP
View source version on accesswire.com: